Chirurgie beim NSCLC im Stadium IIIA (N2)

Surgical Treatment of NSCLC Patients at Stage IIIA (N2). The optimal treat- ment for patients with stage-IIIa (N2) lung can- cer is controversial. Primary surgery for patients with clinically apparent N2 involvement is unsatisfactory with a 5-year survival < 10 %. For this reason, surgery is now seen as part of a neoadjuvant therapeutic approach. Up to 53 % of patients with neoadjuvant chemotherapy ± radiotherapy achieve complete mediastinal res- ponse. In studies, these patients show signifi- cantly better survival rates than patients who did not achieve this effect by means of pretreat- ment. Therefore, patients who have no response to neoadjuvant treatment have poor prognosis and should be operated only in exceptional cases. Interdisz Onkol 2012; 1 (Pre-Publish- ing Online).